Intrapulmonary and intravenous administrations of dihydroergotamine mesylate have similar cardiovascular effects in the conscious dog

British Journal of Pharmacology

Volumn 154, Issue 6, 2008, Pages 1254-1265

  Shrewsbury, S B ^a   Stonerook, M ^b   Okikawa, J K ^a  

^a MAP Pharmaceuticals Inc   (United States)

^b BATTELLE MEMORIAL INSTITUTE   (United States)

Author keywords

Aerosol; Bioavailability; Cardiovascular side effects; Dihydroergotamine; Pharmacokinetic pharmacodynamic model; Pulmonary delivery; Toxicity

Indexed keywords

DIHYDROERGOTAMINE MESILATE;

ANIMAL EXPERIMENT; AORTA; ARTERY RESISTANCE; ARTICLE; BLOOD PRESSURE MEASUREMENT; CARDIOVASCULAR DISEASE; CARDIOVASCULAR EFFECT; CAROTID ARTERY; CONSCIOUSNESS; CORONARY ARTERY; DIASTOLIC BLOOD PRESSURE; DOG; DRUG ADMINISTRATION ROUTE; DRUG BLOOD LEVEL; HEART LEFT VENTRICLE PRESSURE; HEART RATE; INHALATIONAL DRUG ADMINISTRATION; INTRAPULMONARY ARTERY DRUG ADMINISTRATION; MALE; NONHUMAN; PRIORITY JOURNAL; SIMULATION; SYSTOLIC BLOOD PRESSURE; VOMITING;

ANIMALS; AREA UNDER CURVE; BLOOD PRESSURE; CORONARY CIRCULATION; CORONARY VESSELS; DATA INTERPRETATION, STATISTICAL; DIHYDROERGOTAMINE; DOGS; ELECTROCARDIOGRAPHY; HEART RATE; INJECTIONS, INTRA-ARTERIAL; INJECTIONS, INTRAVENOUS; MALE; PULMONARY ARTERY; REGIONAL BLOOD FLOW; VASCULAR RESISTANCE; VASOCONSTRICTOR AGENTS; VENTRICULAR FUNCTION, LEFT;

EID: 47249108513     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1038/bjp.2008.187     Document Type: Article

References (17)

1. Aellig WH (1984). Investigation of the venoconstrictor effect of 8′ hydroxyl DHE, the main metabolite of DHE, in man. Eur J Clin Pharm 26: 239-242.
2. Armer TA, Shrewsbury SB, Newman SP, Pitcairn G, Ramadan N (2007). Aerosol delivery of ergotamine tartrate via a breath-synchronized plume-control inhaler in humans. Curr Med Res Opin 23: 3177-3187.
3. Bendtsen F, Jensen R (2006). Prevalence, burden, and cost of headache disorders. Curr Opin Neurol 19: 281-285.
4. Dodick D, Lipton RB, Martin V, Papademetriou V, Rosamond W, MaassenVanDenBrink A et al. (2004). Consensus statement: cardiovascular safety profile of triptans (5-HT agonists) in the acute treatment of migraine. Headache 44: 414-425.
5. Dowson AJ, Tepper SJ, Dahlof C (2005). Patients' preference for triptans and other medications as a tool for assessing the efficacy of acute treatments for migraine. J Headache Pain 6: 112-120.
6. Ferrari MD, Roon KI, Lipton RB, Goadsby PJ (2001). Oral triptans (serotonin 5-HT(1B/1D) agonists) in acute migraine treatment: a meta-analysis of 53 trials. Lancet 358: 1668-1675.
7. Goadsby PJ, Lipton RA, Ferrari MD (2002). Migraine - current understanding and treatment. N Engl J Med 346: 257-270.
8. Imitrex Label. http://www.fda.gov/cder/foi/label/2001/20132s10lbl.pdf accessed on 4 January 2006.
9. Lipton RB, Bigal ME (2005). Migraine: epidemiology, impact, and risk factors for progression. Headache 45 (Suppl 1): S3-S13.
10. MaassenVanDenBrink A, Reekers M, Bax WA, Ferrari MD, Saxena PR (1998). Coronary side-effect potential of current and prospective antimigraine drugs. Circulation 98: 25-30.
11. Ramadan NM, Buchanan TM (2006). New and future migraine therapy. Pharmacol Ther 112: 199-212.
12. Saper JR, Silberstein S (2006). Pharmacology of dihydroergotamine and evidence for efficacy and safety in migraine. Headache 46: S171-S181.
13. Saper JR, Silberstein S, Dodick D, Rapoport A (2006). DHE in the pharmacotherapy of migraine: potential for a larger role. Headache 46: S212-S220.
14. Shrewsbury SB, Armer TA, Newman SP, Pitcairn G (2006). The Tempo™ Inhaler - results of preliminary tests in humans with a novel pressurized metered-dose inhaler (pMDI) aerosol delivery system. Proc Am Thor Soc 3: A81.
15. Shrewsbury SB, Cook RO, Taylor G, Edwards C, Ramadan NM (2008). Safety and pharmacokinetics of dihydroergotamine mesylate administered via a novel (Tempo™) inhaler. Headache 48: 355-367.
16. Silberstein SD (2000). Practice parameter: evidence-based guidelines for migraine headache (an evidence-based review): Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 55: 754-762.
17. Uchino M, Ishii K, Kuwahara M, Ebukuro S, Tsubone H (2002). Role of the autonomic nervous system in emetic and cardiovascular responses in Suncus murinus. Auton Neurosci 100: 32-40.